zuranolone (Zurzuvae)
Jump to navigation
Jump to search
Indications
- postpartum depression (FDA_approved)
Dosage
Pharmacokinetics
- rapidly-acting antidepressant, benefit within 2 weeks
Adverse effects
- generally well tolerate
- somnolence, headache, sedation, dizziness
Mechanism of action
- analogue of a neuroactive progesterone metabolite with effects GABA brain circuits
More general terms
References
- ↑ Deligiannidis KM et al. Zuranolone for the treatment of postpartum depression. Am J Psychiatry 2023 Jul 26; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37491938 https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.20220785
Deligiannidis KM et al. Effect of zuranolone vs placebo in postpartum depression: A randomized clinical trial. JAMA Psychiatry 2021 Sep 1; 78:951. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34190962 PMCID: PMC8246337 Free PMC article https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2781385